

宏利證券投資信託股份有限公司 函

機關地址：台北市松仁路八十九號六樓

聯絡人及電話：彭曉琪(02) 2757-5622

受文者：宏利環球系列基金各銷售機構

發文日期：2017年10月03日

發文字號：宏投字第106326號

速別：

密等及解密條件或保密期限：

附件：致股東通知書中譯本暨原文版本

主旨：本公司總代理之宏利環球基金修改公開說明書中譯本變動或增加，敬請知悉。

說明：本公司總代理之宏利環球基金之公開說明書將訂於2017年11月17日修訂如下說明：

1. 歐洲聯盟證券借貸交易及再運用之透明性規則之更新：

證券借貸交易及再運用之透明性規則（「SFTR」）已於2016年1月12日生效。

SFTR旨在改進非銀行另類信貸撥備的透明度與監控。經修訂公開說明書之附錄二已新增額外揭露，以澄清目前並不容許證券借貸交易（如SFTR所定義）之投資。倘日後依據SFTR任何子基金獲准進行證券借貸交易，則公開說明書將會納入所有相關資料。

2. 日本增長基金 – 免任投資顧問：

如本公司2015年10月公開說明書之2017年6月第三次增補所揭露，本公司公開說明書內凡提及Manulife Asset Management (Japan) Limited擔任日本增長基金投資經理之投資顧問者（包括其聯絡資料及附錄一有關日本增長基金之相關列表下標題「投資顧問」乙節）已予刪除，經修訂公開說明書亦據此反映該等變動。

正本：華南商業銀行、高雄銀行、臺灣中小企業銀行、渣打國際商業銀行、京城商業銀行、瑞興商業銀行、華泰商業銀行、臺灣新光商業銀行、三信商業銀行、聯邦商業銀行、遠東國際商業銀行、元大商業銀行、凱基商業銀行、大眾商業銀行、日盛國際商業銀行、安泰商業銀行、永豐金證券股份有限公司、元富證券股份有限公司、日盛證券股份有限公司、凱基證券股份有限公司、先鋒投資顧問股份有限公司、基富通證券股份有限公司、鉅亨網證券投資顧問股份有限公司、富盛證券投資顧問股份有限公司、核聚投資顧問股份有限公司、國泰人壽保險股份有限公司、中國人壽保險股份有限公司、南山人壽保險股份有限公司、新光人壽保險股份有限公司、合作金庫人壽保險股份有限公司、三商美邦人壽保險股份有限公司、安聯人壽保險公司、法商法國巴黎人壽保險股份有限公司、全球人壽保險股份有限公司、台灣人壽保險股份有限公司、英屬百慕達商中泰人壽保險股份有限公司台灣分公司、富邦人壽保險股份有限公司、第一金人壽保險股份有限公司

副本：

總經理 張一明

(節譯文僅供參考，與原文相較不盡完整或有歧異，如有疑義應以英文本為準)

(節譯文)

宏利環球基金

可變資本投資公司

註冊營業處所：31, Z.A. Bourmicht, L-8070 Bertrange

盧森堡大公國

本文件乃重要文件並需您即刻留意。若您有任何疑問，應徵詢獨立的專業財務之意見。

致股東通知

(「通知」)

2017年10月3日

親愛的股東

1. 經修訂之公開說明書

謹致函通知您宏利環球基金(「本公司」)之若干重要變動。

該等變動將被反映於日期將訂於2017年11月17日之本公司的經修訂公開說明書(「經修訂公開說明書」)。本通知概述主要的變動供您參閱，並應與包含有關該等變動全部及完整資料之經修訂公開說明書的全文一併閱讀。除另有規定外，本通知所用之詞彙與字句應與經修訂公開說明書所定義者具相同義涵。

為優化本公司之各檔子基金(一檔為「子基金」，合稱「各子基金」)之管理，並能更好地滿足投資人之需求，本公司之董事會(「董事」或「董事會」)已決定進行下列變動，並認為適當：

A. 歐洲聯盟證券借貸交易及再運用之透明性規則之更新

證券借貸交易及再運用之透明性規則(「SFTR」)已於2016年1月12日生效。SFTR旨在改進非銀行另類信貸撥備的透明度與監控。經修訂公開說明書之附錄二已新增額外揭露，以澄清目前並不容許證券借貸交易(如SFTR所定義)之投資。倘日後依據SFTR任何子基金獲准進行證券借貸交易，則公開說明書將會納入所有相關資料。

敬請注意除非上文另有說明，上開變動(i)將不會對各子基金的投資目標、策略及風險狀況有任何影響，(ii)將不會導致本公司及各子基金的運作及/或管理方式有任何變更，(iii)將不會導致任何子基金或其投資人所須承擔的費用有所增加，及

(節譯文僅供參考，與原文相較不盡完整或有歧異，如有疑義應以英文本為準)

(iv)將不會嚴重損害各子基金既存投資人的任何權利或利益；且與前述變動有關之費用及/或開支並不重大，將由本公司負擔之。

2. 日本增長基金 – 免任投資顧問

如本公司 2015 年 10 月公開說明書之 2017 年 6 月第三次增補所揭露，本公司公開說明書內凡提及 Manulife Asset Management (Japan) Limited 擔任日本增長基金投資經理之投資顧問者(包括其聯絡資料及附錄一有關日本增長基金之相關列表下標題「投資顧問」乙節)已予刪除，經修訂公開說明書亦據此反映該等變動。

(略)

鑒於董事之最佳智識與確信(其已盡一切合理注意以確保事實如此)，本通知所載之資料均與事實相符，且無遺漏任何事實有可能影響該等資訊於本通知之日之含義。本公司之董事會願就本通知內容之正確性承擔責任。

代表董事會

This document is important and requires your immediate attention. If in doubt, you should seek independent professional financial advice.

**Notice to Shareholders
("Notice")**

October 3, 2017

Dear Shareholder

1. Revised Prospectus

We are writing to inform you of some important changes to Manulife Global Fund (the "**Company**").

These changes will be reflected in the revised prospectus of the Company (the "**Revised Prospectus**") to be dated November 17, 2017. This Notice, which summarizes the major changes for your easy reference, should be read in conjunction with the full text of the Revised Prospectus which contains full and complete information about these changes. Words and phrases used in this Notice shall, unless otherwise provided, have the same meanings as are ascribed to them in the Revised Prospectus.

The board of directors of the Company (the "**Directors**" or the "**Board**") has decided that it is appropriate to implement the following changes in order to optimize the management of the various sub-funds of the Company (each a "**Sub-Fund**", collectively, the "**Sub-Funds**") and to better meet the needs of investors:-

A. Updates in relation to the European Union Regulation on Transparency of Securities Financing Transactions and of Reuse

The Regulation on Transparency of Securities Financing Transactions and of Reuse ("**SFTR**") came into force on 12 January 2016. The SFTR is aimed at improving the transparency and monitoring of non-bank alternative credit provisions. Additional disclosure has been added to Appendix II of the Revised Prospectus to clarify that investments into securities financing transactions (as defined under the SFTR) are currently not permitted. Should any Sub-Fund in the future be permitted to enter into securities financing transactions, all the relevant information will be included in the Prospectus, in accordance with the SFTR.

Please note that, except as otherwise described above, the above changes (i) will have no effect on the investment objective, strategy and risk profiles of the Sub-Funds, (ii) will not result in any change in the operations and/or manner in which the Company and the Sub-Funds are being managed, (iii) will not lead to an increase in the fees to be borne by any of the Sub-Funds or their investors, and (iv) will not materially prejudice any of the rights or interests of the existing investors of the Sub-Funds; and costs and/or expenses relating to the above changes will not be material and will be borne by the Company.

2. Japanese Growth Fund – Removal of Investment Advisor

As previously disclosed pursuant to the Third Addendum to the Prospectus dated October 2015 and the Hong Kong Covering Document dated 1 October 2015 of the Company, dated June 2017, all references to Manulife Asset Management (Japan) Limited acting as the Investment Adviser to the Investment Manager of the Japanese Growth Fund (including its contact details and the section entitled "Investment Adviser" in the relevant table in Appendix I which relates to the Japanese Growth Fund) that appear in the prospectus of the Company have been removed and such changes are accordingly reflected in the Revised Prospectus.

General

For Hong Kong Shareholders Only: Subject to the approval of the Hong Kong Securities and Futures Commission (the "**SFC**"), the Company's prospectus and the Hong Kong Covering Document (together with the Product Key Facts Statement of each Sub-Fund, the "**Hong Kong Offering Documents**") will be updated to reflect changes to the Company. The Hong Kong Offering Documents and (where applicable) the latest annual

and semi-annual reports of the Company (if any) are available and may be inspected and/or copies obtained, free of charge during usual business hours from the office of the Hong Kong Representative at 50th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong SAR. The Hong Kong Offering Documents are also available at www.manulifefunds.com.hk. Please note that this website has not been reviewed by the SFC and may contain information on funds which are not authorized by the SFC and are, thus, not available to retail investors in Hong Kong.

Shareholders requiring further information about any of the matters set out in this Notice may contact the Administrator of the Company, Citibank Europe plc, Luxembourg Branch, at telephone number (352) 45 14 14 258 or fax number (352) 45 14 14 332 or the Hong Kong Distributor, Manulife Asset Management (Hong Kong) Limited, of 16th Floor, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong, at telephone number (852) 2108 1110 or fax number (852) 2810 9510 at any time during normal business hours.

To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Notice is in accordance with the facts and does not omit anything likely to affect the import of such information as at the date of this Notice. The Directors accept responsibility for the accuracy of the contents of this Notice accordingly.

For and on behalf of the Board